594 related articles for article (PubMed ID: 10830736)
1. Detection of residual disease in pediatric B-cell precursor acute lymphoblastic leukemia by comparative phenotype mapping: method and significance.
Dworzak MN; Fritsch G; Panzer-Grümayer ER; Mann G; Gadner H
Leuk Lymphoma; 2000 Jul; 38(3-4):295-308. PubMed ID: 10830736
[TBL] [Abstract][Full Text] [Related]
2. Expression of CD58 in normal, regenerating and leukemic bone marrow B cells: implications for the detection of minimal residual disease in acute lymphocytic leukemia.
Veltroni M; De Zen L; Sanzari MC; Maglia O; Dworzak MN; Ratei R; Biondi A; Basso G; Gaipa G;
Haematologica; 2003 Nov; 88(11):1245-52. PubMed ID: 14607753
[TBL] [Abstract][Full Text] [Related]
3. Detectable molecular residual disease at the beginning of maintenance therapy indicates poor outcome in children with T-cell acute lymphoblastic leukemia.
Dibenedetto SP; Lo Nigro L; Mayer SP; Rovera G; Schilirò G
Blood; 1997 Aug; 90(3):1226-32. PubMed ID: 9242556
[TBL] [Abstract][Full Text] [Related]
4. [The clinical significance of detecting minimal residual disease in acute childhood B-cell lymphoblastic leukemia with flow cytometry].
Zhang LP; Cheng YF; Liu GL; Lu AD; Liu YR; Wang H
Zhonghua Er Ke Za Zhi; 2005 Jul; 43(7):481-5. PubMed ID: 16083543
[TBL] [Abstract][Full Text] [Related]
5. Minimal residual disease analysis by eight-color flow cytometry in relapsed childhood acute lymphoblastic leukemia.
Karawajew L; Dworzak M; Ratei R; Rhein P; Gaipa G; Buldini B; Basso G; Hrusak O; Ludwig WD; Henze G; Seeger K; von Stackelberg A; Mejstrikova E; Eckert C
Haematologica; 2015 Jul; 100(7):935-44. PubMed ID: 26001791
[TBL] [Abstract][Full Text] [Related]
6. Detection of residual disease in pediatric B-cell precursor acute lymphoblastic leukemia by comparative phenotype mapping: a study of five cases controlled by genetic methods.
Dworzak MN; Stolz F; Fröschl G; Printz D; Henn T; Fischer S; Fleischer C; Haas OA; Fritsch G; Gadner H; Panzer-Grümayer ER
Exp Hematol; 1999 Apr; 27(4):673-81. PubMed ID: 10210325
[TBL] [Abstract][Full Text] [Related]
7. Flow-cytometric minimal residual disease monitoring in blood predicts relapse risk in pediatric B-cell precursor acute lymphoblastic leukemia in trial AIEOP-BFM-ALL 2000.
Schumich A; Maurer-Granofszky M; Attarbaschi A; Pötschger U; Buldini B; Gaipa G; Karawajew L; Printz D; Ratei R; Conter V; Schrappe M; Mann G; Basso G; Dworzak MN;
Pediatr Blood Cancer; 2019 May; 66(5):e27590. PubMed ID: 30561169
[TBL] [Abstract][Full Text] [Related]
8. No prognostic significance of immunophenotypic changes at the end of remission induction therapy in children with B-lineage acute lymphoblastic leukemia.
Dai Q; Liu X; Yang H; Guo S; Wang Y; Peng L; Ye L; Chen L; Lai C; Chen Q; Zhang G; Jiang Y
Leuk Res; 2018 May; 68():57-61. PubMed ID: 29544133
[TBL] [Abstract][Full Text] [Related]
9. Flow cytometric follow-up of minimal residual disease in bone marrow gives prognostic information in children with acute lymphoblastic leukemia.
Björklund E; Mazur J; Söderhäll S; Porwit-MacDonald A
Leukemia; 2003 Jan; 17(1):138-48. PubMed ID: 12529671
[TBL] [Abstract][Full Text] [Related]
10. [Clinical significance for minimal residual disease detection by 4 color flow cytometry in adult and childhood B lineage acute lymphoblastic leukemia].
Liu YR; Zhang LP; Chang Y; Cheng YF; Fu JY; Li LD; Wang H; Liu GL; Chen SS; Huang XJ; Lu DP
Zhonghua Xue Ye Xue Za Zhi; 2006 May; 27(5):302-5. PubMed ID: 16875577
[TBL] [Abstract][Full Text] [Related]
11. CD304/neuropilin-1 is a very useful and dependable marker for the measurable residual disease assessment of B-cell precursor acute lymphoblastic leukemia.
Gudapati P; Khanka T; Chatterjee G; Ghogale S; Badrinath Y; Deshpande N; Patil J; Narula G; Shetty D; Banavali S; Patkar NV; Gujral S; Subramanian PG; Tembhare PR
Cytometry B Clin Cytom; 2020 Jul; 98(4):328-335. PubMed ID: 31944572
[TBL] [Abstract][Full Text] [Related]
12. Standardizing minimal residual disease by flow cytometry for precursor B lineage acute lymphoblastic leukemia in a developing country.
Patkar N; Alex AA; B B; Ahmed R; Abraham A; George B; Vishwabandya A; Srivastava A; Mathews V
Cytometry B Clin Cytom; 2012 Jul; 82(4):252-8. PubMed ID: 22467604
[TBL] [Abstract][Full Text] [Related]
13. A limited antibody panel can distinguish B-precursor acute lymphoblastic leukemia from normal B precursors with four color flow cytometry: implications for residual disease detection.
Weir EG; Cowan K; LeBeau P; Borowitz MJ
Leukemia; 1999 Apr; 13(4):558-67. PubMed ID: 10214862
[TBL] [Abstract][Full Text] [Related]
14. Immunophenotypic shift in the B-cell precursors from regenerating bone marrow samples: A critical consideration for measurable residual disease assessment in B-lymphoblastic leukemia.
Chatterjee G; Sriram H; Ghogale S; Deshpande N; Khanka T; Panda D; Pradhan SN; Girase K; Narula G; Dhamane C; Malik NR; Banavali S; Patkar NV; Gujral S; Subramanian PG; Tembhare PR
Cytometry B Clin Cytom; 2021 Jul; 100(4):434-445. PubMed ID: 32896101
[TBL] [Abstract][Full Text] [Related]
15. Prognostic value of immunophenotypic detection of minimal residual disease in acute lymphoblastic leukemia.
Ciudad J; San Miguel JF; López-Berges MC; Vidriales B; Valverde B; Ocqueteau M; Mateos G; Caballero MD; Hernández J; Moro MJ; Mateos MV; Orfao A
J Clin Oncol; 1998 Dec; 16(12):3774-81. PubMed ID: 9850021
[TBL] [Abstract][Full Text] [Related]
16. Monitoring minimal/measurable residual disease in B-cell acute lymphoblastic leukemia by flow cytometry during targeted therapy.
Liu Z; Li Y; Shi C
Int J Hematol; 2021 Mar; 113(3):337-343. PubMed ID: 33502735
[TBL] [Abstract][Full Text] [Related]
17. Immunophenotypic Modulation of the Blast Cells in Childhood Acute Lymphoblastic Leukemia Minimal Residual Disease Detection.
Burnusuzov HA; Spasova MI; Murdjeva MA; Stoyanova AA; Mumdziev IN; Kaleva VI; Belcheva MI; Bosheva MN
Folia Med (Plovdiv); 2016 Mar; 58(1):28-35. PubMed ID: 27383875
[TBL] [Abstract][Full Text] [Related]
18. [Clinical research on clearance of leukemic cell during induction of remission therapy in children with precursor B cell acute lymphoblastic leukemia].
Yi ZG; Cui L; Gao C; Jin M; Zhang RD; Li ZG; Wu MY
Zhonghua Er Ke Za Zhi; 2011 Mar; 49(3):170-4. PubMed ID: 21575363
[TBL] [Abstract][Full Text] [Related]
19. Immunophenotypic modulation in pediatric B lymphoblastic leukemia and its implications in MRD detection.
Thulasi Raman R; Anurekha M; Lakshman V; Balasubramaniam R; Ramya U; Revathi R
Leuk Lymphoma; 2020 Aug; 61(8):1974-1980. PubMed ID: 32281503
[TBL] [Abstract][Full Text] [Related]
20. Overexpression of CD49f in precursor B-cell acute lymphoblastic leukemia: potential usefulness in minimal residual disease detection.
DiGiuseppe JA; Fuller SG; Borowitz MJ
Cytometry B Clin Cytom; 2009 Mar; 76(2):150-5. PubMed ID: 18831072
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]